Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May;20(5):3696-3704.
doi: 10.1002/alz.13811. Epub 2024 Apr 4.

Plasma oxysterols are associated with serum lipids and dementia risk in older women

Affiliations

Plasma oxysterols are associated with serum lipids and dementia risk in older women

Michelle M Dunk et al. Alzheimers Dement. 2024 May.

Abstract

Introduction: Apolipoprotein E4 (APOE4) carriers' tendency toward hypercholesterolemia may contribute to Alzheimer's disease (AD) risk through oxysterols, which traverse the blood-brain barrier.

Methods: Relationships between baseline plasma oxysterols, APOE status, serum lipids, and cognitive impairment risk were examined in 328 postmenopausal women from the Women's Health Initiative Memory Study. Women were followed for 25 years or until incident dementia or cognitive impairment.

Results: Levels of 24(S)-hydroxycholesterol (24-OHC), 27-hydroxycholesterol (27-OHC), and 24-OHC/27-OHC ratio did not differ by APOE status (p's > 0.05). Higher 24-OHC and 27-OHC were associated with higher total, low density lipoprotein (LDL), non-high density lipoprotein (HDL), remnant, LDL/HDL, and total/HDL cholesterol and triglycerides (p's < 0.05). Higher 24-OHC/27-OHC was associated with greater dementia risk (hazard ratio = 1.51, 95% confidence interval:1.02-2.22), which interaction analyses revealed as significant for APOE3 and APOE4+, but not APOE2+ carriers.

Discussion: Less favorable lipid profiles were associated with higher oxysterol levels. A higher ratio of 24-OHC/27-OHC may contribute to dementia risk in APOE3 and APOE4+ carriers.

Keywords: 24‐hydroxycholesterol; 27‐hydroxycholesterol; Alzheimer's disease; Apolipoprotein E; Women's Health Initiative Memory Study; cholesterol; dementia; mild cognitive impairment; oxysterols.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest. Author disclosures are available in the supporting information.

References

    1. Serrano‐Pozo A, Das S, Hyman BT. APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches. Lancet Neurol. 2021;20(1):68‐80. doi:10.1016/S1474-4422(20)30412-9 - DOI - PMC - PubMed
    1. Chartier‐Harlin M‐C, Parfitt M, Legrain S, et al. Apolipoprotein E, ε4 allele as a major risk factor for sporadic early and late‐onset forms of Alzheimer's disease: analysis of the 19q13.2 chromosomal region. Hum Mol Genet. 1994;3(4):569‐574. - PubMed
    1. Boerwinkle E, Sing CF. The use of measured genotype information in the analysis of quantitative phenotypes in man. III. Simultaneous estimation of the frequencies and effects of the apolipoprotein E polymorphism and residual polygenetic effects on cholesterol, betalipoprotein and triglyceride levels. Ann Hum Genet. 1987;51(3):211‐226. doi:10.1111/j.1469-1809.1987.tb00874.x - DOI - PubMed
    1. Bennet AM, Di Angelantonio E, Ye Z, et al. Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA. 2007;298(11):1300‐1311. doi:10.1001/jama.298.11.1300 - DOI - PubMed
    1. Anstey KJ, Ashby‐Mitchell K, Peters R. Updating the evidence on the association between serum cholesterol and risk of late‐life dementia: review and meta‐analysis. J Alzheimers Dis. 2017;56:215‐228. doi:10.3233/JAD-160826 - DOI - PMC - PubMed

Publication types